Selinexor-based treatments are associated with increased expression of T-cell activation markers in multiple myeloma
Authors:
- Yubin KangYKYubin Kang
- Jadee L. NeffJNJadee L. Neff
- Andrea ElleroAEAndrea Ellero
- William R. JeckWJWilliam R. Jeck
- Cristina GasparettoCGCristina Gasparetto
- Xiaobei WangXWXiaobei Wang
- Xufeng ChenXCXufeng Chen
- Zuowei SuZSZuowei Su
- Christopher J. WalkerCWChristopher J. Walker
Open Access
- 23 September 2025
- journal article
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 1 (3)
Abstract
No abstract availableThis publication has 58 references indexed in Scilit:
- The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patientsCancer Cell, 2023
- Bim downregulation by activation of NF-κB p65, Akt, and ERK1/2 is associated with adriamycin and dexamethasone resistance in multiple myeloma cellsClinical and Experimental Medicine, 2022
- Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myelomaeJHaem, 2020
- The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myelomaCellular Immunology, 2019
- The challenges of checkpoint inhibition in the treatment of multiple myelomaCellular Immunology, 2018
- Myeloid-derived suppressor cells: The green light for myeloma immune escapeBlood Reviews, 2016
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune RegulationImmunity, 2016
- Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal BiogenesisMolecular Cell, 2012
- Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancerCancer, 2008
- CD4, CD8 and the role of CD45 in T-cell activationCurrent Opinion in Immunology, 1993